Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Agilent Technologies has recovered sharply from last week's 3.3% pullback, closing at $171.60 and drawing fresh analyst upgrades that suggest the Street is using dips as entry points rather than exit signals.
The most notable development this week is the analyst community pressing harder on price targets. TD Cowen's Dan Brennan lifted his target from $180 to $196 yesterday, maintaining Buy, while Morgan Stanley raised to $190 from $175 the same day, keeping Overweight. That follows Barclays lifting to $195 just a week ago. All three moves came with no rating changes, a pattern that reads more as growing confidence in the earnings trajectory than a reflexive re-rating. The consensus mean is now $180.30, still about 5% below the $196 ceiling from Cowen. At 25.9x trailing earnings and an EV/EBITDA of 21.1x, neither multiple is cheap, but both have expanded roughly 14% and the EV/EBITDA has been broadly stable over the past month, suggesting the market is paying for the growth story without panic-buying the multiple. The bull case has three pillars: synchronized product cycles across liquid and gas chromatography and the new ICP-MS funnel, pharma reshoring demand where five of the top ten pharma customers have already ordered and revenues are expected from 2027, and Q3 organic growth of 7.3%. Bears focus on China, which accounts for around 18% of sales against a peer average of roughly 12%, and on tariff and macro sensitivity given approximately 25% of revenue tied to chemical and advanced materials.
Short interest is genuinely low and not the story here. Bears hold roughly 1.9% of the free float, a level that has edged up around 3% over the past month but remains well below any threshold of concern. Borrow availability is as loose as it gets, with availability at the system ceiling and cost to borrow running at just 0.63%, even as that rate has climbed 62% over the past week. That week-on-week spike in CTB is worth noting, but at 0.63% absolute the borrow market is far from stressed. Options positioning is similarly unremarkable. The put/call ratio of 0.77 is almost exactly in line with its 20-day average of 0.76, and the z-score of 0.26 is near neutral. There is no hedging anxiety building in the options market ahead of the November 25 earnings date.
Peer performance provides useful context for the week's move. TMO gained 1% on the week while MTD added 4.2% and DHR rose 3.4%. Agilent's 1.3% weekly gain looks modest against that group, and BRKR fell 7.1% on the week, a reminder that the instrument sector is not uniformly in favour. Agilent's relative steadiness during the prior month's selloff and its recovery this week point to an underlying bid from long-only holders. BlackRock holds 9.1% and added 203,000 shares as recently as end of September. FMR built a position of around 1.6% of shares over the same period, adding over four million shares, the largest single institutional add in the recent data. Insider activity is thin and inconsequential: the only EDGAR-filed transactions in the past 90 days were a small director grant and a director disposal of under $100,000. No executive is buying or selling with any conviction.
Wikipedia attention for the stock, the one available alt-data signal, ran about 1.4 standard deviations above its own 90-day baseline as of late September, which reflects elevated retail attention rather than a revenue indicator. No alt-data dataset covering Agilent has been measured to lead its reported financials.
The next earnings print on November 25 is the natural checkpoint. With targets now clustered in the $190 to $196 range and the stock at $171.60, the Street is pricing in a further re-rating contingent on the company sustaining the Q3 organic growth trajectory while managing China volatility and tariff drag into Q4.
See the live data behind this article on ORTEX.
Open A on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
